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Background: Pharmaceuticals’ relative effectiveness has come to the fore in the policy arena, reflecting the need to understand how relative efficacy (what can work) translates into
added benefit in routine clinical use (what does work). European payers and licensing authorities assess value for money and post-launch benefit–risk profiles, and efforts to
standardize assessments of relative effectiveness across the European Union (EU) are under way. However, the ways that relative effectiveness differs across EU healthcare settings
are poorly understood.
Methods: To understand which factors influence differences in relative effectiveness, we developed an analytical framework that treats the healthcare system as a health production
function. Using evidence on breast cancer from England, Spain, and Sweden as a case study, we investigated the reasons why the relative effectiveness of a new drug might vary
across healthcare systems. Evidence was identified from a literature review and national clinical guidance.
Results: The review included thirteen international studies and thirty country-specific studies. Cross-country differences in population age structure, deprivation, and educational
attainment were consistently associated with variation in outcomes. Screening intensity appeared to drive differences in survival, although the impact on mortality was unclear.
Conclusions: The way efficacy translates into relative effectiveness across health systems is likely to be influenced by a range of complex and interrelated factors. These factors could
inform government and payer policy decisions on ways to optimize relative effectiveness, and help increase understanding of the potential transferability of data on relative
effectiveness from one health system to another.
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Relative effectiveness can be defined as “the extent to which
an intervention does more good than harm compared with one
or more alternative interventions under the usual circumstances
of healthcare practice” (1). This contrasts with relative efficacy,
which is a comparison “under ideal circumstances,” which is
usually associated with controlled clinical trials (2). “Compar-
ative effectiveness” is closely related to relative effectiveness
(3).
Towse et al. (3) propose an analytical framework, which
draws upon production function theory, that describes how cer-
tain sets of inputs and processes yield specified outcomes. The
aim is to systematically identify and quantify the potential de-
terminants of relative effectiveness. This study reports a first
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assessment of the framework to help understand the contex-
tual differences between countries that could be associated with
differences in effectiveness and relative effectiveness. In recog-
nition of ongoing efforts to develop EuropeanUnion (EU) -level
approaches to assessment, our case study focuses on breast can-
cer in three countries in the EU.
OBJECTIVE
To highlight potential cross-country differences in the relative
effectiveness of a new drug we reviewed studies investigating
reasons for differences in health outcomes in breast cancer. We
also reviewed relevant national clinical guidelines and health
technology assessment (HTA) reports to understand similarities
and differences in the management of breast cancer. We show
how our analytical framework can help to understand the fac-
tors that might drive differences in relative effectiveness across
different settings.
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METHODS
In a separate study in this issue (3), we set out an analytical
framework that uses a health production function approach,
with health as the output of interest (4). Inputs (“factors” or
“determinants”) are classified according to the level at which
they operate: patient level (i.e., individuals’ clinical or socio-
demographic characteristics); provider level; and the level of the
healthcare environment or system. The relative effectiveness of
a drug is the additional net output (health) achieved by adding a
new drug to usual care or substituting it for another treatment.
In this study, we use breast cancer as a case study to identify ev-
idence on the factors associated with health outcomes, drawing
on findings from England, Spain, and Sweden.
In selecting a disease area for our case study, we considered
several potential tracer conditions including cardiovascular dis-
ease, Alzheimer’s disease, schizophrenia, cancer, osteoporosis,
and rheumatoid arthritis. We selected breast cancer because it
is a common condition, is a high clinical priority in all three
countries, and new drugs enter the market regularly. Outcomes
are driven by both drug and nondrug interventions, as well as by
the coordination of care across different settings, and the care
pathway covers prevention, early detection, diagnosis, surgery,
and adjuvant therapy.
The selection of countries was mainly driven by the like-
lihood that data would be available for most of the factors we
wanted to investigate. We, therefore, decided to limit our choice
to countries with similar gross domestic product (high income
countries), that had good data on usage and cost, and that var-
ied in technology diffusion and health outcomes. Pragmatically,
national clinical guidelines would be accessible only if pub-
lished in English, Spanish, or Swedish, and this factor helped
us to finalize our selection. Our three study countries, England,
Spain, and Sweden, have published clinical guidelines on breast
cancer, which provide an indication of national priorities and
inputs that may influence outcomes. Two of the three countries
(England and Sweden) have also assessed the cost-effectiveness
of (some) breast cancer drugs.
To identify the data that would be needed to populate a
health production model for breast cancer, we undertook a re-
view of the literature. We also reviewed national clinical guide-
lines and HTA reports.
Literature Review
A recent review of studies explored the extent of any variation
in relative efficacy and relative effectiveness of medicines used
in one or more EU Member States (5). The review found little
empirical evidence on cross-country differences, and no cross-
border observational studies to compare effectiveness in routine
practice. For the purpose of this article, we, therefore, simpli-
fied our approach: focusing on breast cancer, we searched for
studies that investigated determinants of health outcomes such
as mortality or quality of life in one or more of our countries
Table 1. Terms Used in the Electronic Search Strategy
Term category Examples
Illness terms Breast cancer/neoplasm/ carcinoma
Health outcomes terms Mortality/ survival/death rates, quality of life, health
related quality of life (HRQL) and life expectancy
Setting terms England, Spain and Sweden or cross-country,
international, comparison, benchmarking
Generic terms for factors Cause, driver, explanatory, covariate, determinant, etc.
Study design Time trends/series analysis, regression/survival/logistic
models multivariate/bivariate/univariate analysis.
Note. Both interventional (experimental) and observational studies were eligible for
inclusion. The search strategy used for Medline is available online (Supplementary
file 1).
of interest (Sweden, Spain, the United Kingdom). We included
regression analyses and registry studies published between Jan-
uary 2000 and August 2011. The search strategy was designed
for Medline based on key search terms agreed by three of the
authors (Table 1) and then adapted to run on EMBASE. The
Medline strategy is available in online Supplementary Table 1.
Titles and abstracts from the searches were screened for el-
igibility by two of the review team (R.P.P., A.M.). To be eligible
for inclusion, studies needed to explicitly investigate determi-
nants driving differences in outcomes, either across countries
(international comparative studies) or within countries (individ-
ual country studies). Potentially eligible studies were identified
by two authors (R.P.P., A.M.) and assessed for inclusion by
one author (RPP). Figure 1 shows the study selection process.
One member of the review team (R.P.P.) extracted the data from
each study into a template, providing details of the study design,
countries covered by the study, data sources, health outcomes
and findings (see online Supplementary Tables 1 and 2). As
shown in Table 2, the factors identified were then grouped into
the framework categories reflecting the level of influence (in-
dividual, provider, and national level) using the template from
Table 1 in Towse et al. 2015 (3). These data were checked by a
second reviewer (A.M.).
Clinical Guidance Review
To identify similarities and differences in recommended care
pathways across our study countries, clinical guidelines for the
treatment of breast cancer and relevant HTA reports were re-
viewed. We searched the Web sites of national HTA agencies
(England and Wales, Sweden), Ministries of Health (Spain)
and Royal Colleges (Spain), and consulted experts (Sweden).
Comparative data on screening programs, and treatment recom-
mendations by stage of disease were extracted and tabulated.
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Figure 1. Flow diagram showing the selection process for studies included in the literature review.
RESULTS
Forty-three studies were included in the literature review. Thir-
teen of these forty-three were international comparative studies
that covered at least two of the three countries in our case study
(6–18). The remaining thirty studies were national, investigat-
ing individual countries. Nine studies covered England (19–27),
four were set in Spain (28–31), and seventeen were set in Swe-
den (32–48).
The review of national guidance (either clinical guidelines
or HTA reports) identified five documents on breast cancer
care for England and Wales (49–53), three from Spain (54–56),
and six from Sweden (57–62). The Cancer Strategy document
published by the Spanish Ministry of Health (54) makes no
treatment-specific recommendations, so we also reviewed the
two Spanish Society of Medical Oncology (SEOM) guidelines
(55;56) although these are not “official” guidance. In all coun-
tries, guidelines covered the whole disease pathway incorporat-
ing early, advanced, and metastatic disease.
Table 2 provides an overview of factors affecting breast
cancer outcomes identified from the literature review. It groups
them according to the multilevel approach: “individual level,”
“provider level,” and “environment and healthcare system level”
set out in Towse et al. (3) (Table 1). The table lists the studies
that either tested for determinants, or commented on them. We
discuss the key factors below.
Individual Level Factors
At the individual level, several demographic factors were con-
sistently associated with poorer outcomes in breast cancer pa-
tients, including older age, socio-economic status, and lifestyle
factors (smoking status). Older women (aged 75 and over) had
lower survival rates than youngerwomen.Although this is partly
explained by stage at diagnosis (13)—older women are more
likely to present with late stage disease—a Swedish study found
that survival differences persisted and were more pronounced
in older women with late stage disease than clinically compa-
rable (but younger) women. Older women underwent less in-
tensive diagnostic activity, and less aggressive treatment, even
after adjusting for comorbidity (33). Evidence from England
and Sweden suggested that women with lower socio-economic
status have worse survival, after adjusting for tumor size and
3 INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 31:5, 2015
Puig-Peiro et al.
Table 2. Factors Affecting Breast Cancer Outcomes: Findings from the Review
Influence level Category Key findings Study references
Individual / patient level
factor
Demographic
characteristics
Age: Older patients tend to have worse prognosis and therefore lower survival rates. This is partly due
to greater co-morbidity, but the observed large differences in the intensity of treatment of older
patients cannot be explained by co-morbidity alone.
(6; 13; 15; 30; 33)
Lifestyle: Smoking, diet and other lifestyle characteristics (number of children, age at first pregnancy,
age at menarche and menopause, etc.) are different across populations.
(8; 10; 11; 17; 44)
Socio-economic status: Women with higher socio-economic status (i.e. with higher income, more
skilled work and a high level of education) have a statistically significantly higher survival rate, even
after adjustment for tumor size and age at diagnosis.
(9; 19; 21; 27; 35; 36;
39; 40; 42; 46)
Clinical characteristics Stage at diagnosis is an important predictor of differences in 5-year relative survival rates across
countries (after adjusting for age, all-cause mortality, number of nodes examined at diagnosis and
surgery).
(7; 10; 12–15; 19; 30;
48)
Co-morbidity: Some treatment options (radiotherapy or chemotherapy) may be contraindicated
because of specific co-morbidities.
(10; 33)
Tumor pathology affects breast cancer outcomes (13)
Genetics: Cancer-specific survival in parents predicts survival from the same cancer in their children. (37; 38; 43)
Provider level factors Provider characteristics Differences in medical practice and treatments can influence survival rates. (13; 15; 33)
Access to hospitals Delayed time to diagnosis and long waiting lists negatively impact cancer survival. (10; 17; 18; 24; 28)
Access to ambulatory care: longer travel time to the GP associated with late stage at diagnosis of
breast cancer, after adjusting for age, sex, and deprivation.
(20)
Introduction of multidisciplinary teams associated with improvements in processes of care for breast
cancer patients, but not with improved survival.
(6; 23; 25)
Data quality / comparability: there are differences between countries in the methods and specificity of
certifying cause of death which partially explains differences in reported breast cancer mortality rates.
(6; 8)
Environment/ health care
system level factors
Population health Infant and total mortality rates; life expectancy at birth; unemployment rate independently and
significantly associated with cancer survival.
(6; 15; 16)
Awareness of symptoms may lead to early diagnosis and access treatment improving the health
outcomes
(10)
The distribution of tumor biology can differ across populations and lead to differences in cancer
outcomes across countries.
(7)
National /regional
guidelines/
regulations
Site-specialist multidisciplinary teams introduced as part of a national initiative changed treatment
patterns and increased surgical specialization, but the improvement in survival rates was not
statistically significant.
(23; 25)
Service delivery and
organisation
Screening intensity is associated with increased incidence of early stage breast cancer, which in turn
leads to improved overall survival rates (lead time bias, length time bias). Improved mortality rates
are less evident.
(6–9; 11; 12; 17; 26;
29; 32; 34; 41; 45;
47; 48)
Access issues
(local/regional/
national)
Diagnosis and treatment: Inequalities of access can be partly explained by the national total
expenditure on healthcare. Lower use of radiotherapy may adversely affect cancer outcomes. Fewer
GPs per thousand population is associated with delays in diagnosis of cancer and worsened prognosis.
(6; 10–13; 15; 17; 18;
28; 29; 31)
Hospital equipment / beds: Number of in-patient beds; number of computerized tomography (CT)
scanners per million population positively associated with survival rates.
(16)
Economy Income and expenditure: Positive association between survival rates and countries’ national income;
expenditure on health as a proportion of GNP; and public expenditure on health as percentage of
total health expenditure.
(7; 12; 13; 16; 18)
Environment Sunlight: Patients diagnosed in summer and autumn have a longer survival than patients diagnosed in
winter. Vitamin D levels play a relevant role in tumor growth suppression.
(22)
Note. Two international studies (8; 14)and one based in Spain (31) discussed the quality and efficacy of care in relation to their findings but none formally tested for it.
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age (19;42) and that better educated women are likely to have a
better prognosis (39;40). A Swedish study found that smoking
status independently increased the risk of death (after adjusting
for age and stage of disease) (44). We found no direct evidence
on treatment concordance (adherence).
In terms of individuals’ clinical characteristics, there was
strong evidence that disease stage at diagnosis is an important—
and perhaps the most important—predictor of cross-country
differences in 5-year survival. However, stage at diagnosis is
not, in itself, an “explanation”; rather, it begs the question of
why disease stage differs across countries. Possible reasons in-
clude screening intensity, access to diagnosis and treatment, and
public awareness (which we consider below). Tumor pathol-
ogy, in particular, the proportion of women with node negative
disease, accounts for some differences in survival (13), and
Swedish studies found that genetic (familial) determinants also
affect prognosis and survival (37;38;43). Women with specific
comorbidities may have fewer treatment options, for instance
if they are unsuitable for radiotherapy or chemotherapy (33).
However, we found no study that explicitly tested the impact of
co-morbidity on survival.
Provider Level Factors
There was less evidence on which features of the healthcare
system influence survival, and our searches found no cross-
country analyses. Studies from England have investigated the
role played by access (travel time) and by multidisciplinary
teams (MDTs). Travel time to the GP (general practitioner) was
correlated with stage at diagnosis, but there was no consistent
relationship between travel time to hospital and survival or stage
at diagnosis (20). MDTs improved the process of care but did
not significantly improve survival at 1, 3, or 5 years (23;25).
However, if average survival for a breast cancer patient is around
7 to 8 years after diagnosis (15), longer follow-up periods may
be needed to detect an effect.
Other studies have considered access to diagnostic facilities
and to treatments, and waiting times between symptom onset
and treatment. The importance of access to diagnostic facilities
is well-recognized, and we discuss this in relation to screening
programs (see below). An English study analyzed data from
the Northern and Yorkshire Cancer Registry and Information
Service (NYCRIS) to compare 3-year survival rates for those
diagnosed between 1982 and 1990 with cases diagnosed be-
tween 1991 and 1999 (24). In all age groups, 3-year survival
improved significantly between the two periods. Stage at diag-
nosis explained all the improvement in those aged over 65, and
explained most of the improvement in women aged below 65.
Although the uptake of systemic treatment (chemotherapy and
hormone treatment) increased substantially over time, systemic
treatment had no statistically significant effect in explaining
improvements in prognosis in any age group or overall. How-
ever, there are several reasons why this “negative” finding for
treatment effect needs to be interpreted carefully. First, 3-year
survival may be too short a time to robustly assess the impact
of systemic therapy on mortality. In addition, data on stage at
diagnosis were missing for a large proportion of cases, partic-
ularly in the earlier period. This “stage migration” could have
led to greater misclassification bias in the first period, which
could, therefore, overstate the role of stage in explaining sur-
vival improvement. Lastly, the study did not test for an interac-
tion between stage at diagnosis and treatment uptake, so did not
isolate the effect of earlier treatment per se. Further details of
this study (24) are available in online Supplementary Table 1.
Finally, the quality and consistency of data recording is
known to vary across countries, and there are differences be-
tween countries in the methods and specificity of certifying
cause of death (6;8). However, a recent analysis found that even
“implausibly extreme” assumptions about data errors could not
account for all the observed cross-country differences in sur-
vival (18).
National / Environmental Factors
There are national screening programs in operation in Eng-
land and Wales (63) and in Sweden (64). In Spain, screening
programs are managed and run on a regional basis. Table 3 sum-
marizes the characteristics of the screening programs in terms
of the target population and screening interval, based on the
review of clinical guidelines.
The intensity of screening activity was strongly associated
with improved survival, although evidence for an impact on
mortality rates was mixed (6;32). Both national screening pro-
grams and opportunistic screening increased the incidence of
early stage breast cancer. This improves overall survival rates,
reflecting both the effect of earlier treatment and lead time bias.
However, countries that have not introduced screening have also
seen improvements in survival (6;8), suggesting that other fac-
tors play a role.
Evidence on the role of national guidelines was sparse, in
terms of both the extent of implementation and the effect on
outcomes. Our review of national guidance found few differ-
ences in recommendations for treatment of breast cancer, but
variation in the date of issue and of the scope of guidance,
as well as its implementation, may be important. A Swedish
study investigated regional differences in survival, and found
that suboptimal diagnostic activity in one county explained the
variation. Services were reorganized in this county: multidisci-
plinary working was better staffed and co-ordinated, screening
and diagnostic activity were quality assured, and treatment rec-
ommendations were implemented. When guideline adherence
improved in these ways, survival also improved (34). An eval-
uation of the effects of 1995 Calman-Hine report, which intro-
duced national cancer guidelines, found that adherence varied
across English regions (23). A study found evidence that care
processes had improved as a result of both the Calman-Hine
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Table 3. Breast cancer screening policy in three European countries
England (and Wales) Spain Sweden
Competency National (NHSBSP) Regional National (but with regional
differences)
Start date 1988 1989 (8) 1986
Target population (age) 50–70
• Women aged 40–50 invited for
annual mammography if at
significant risk
• Women>70 years: not invited but
can self-refer every three years
• eligibility to be extended to 47–73
years by 2016
50–69 (54) 40–74
• All women aged 50–69
• 60–70% of counties also invite
women aged 40–49
• 50% counties also invite women
aged 70–74 (65)
Screening interval Every three years Every two years 18–24 months, depending on age
% estimated uptake in target population (year assessed) (64) 75% (2008) 64% (2006) 80% (2008)
Notes: NHSBSP: National Health Service Breast Screening Programme (http://www.cancerscreening.nhs.uk/breastscreen/)
Sources: Botha 2003 (8); Ministerio de Sanidad y Politica Social 2010 (54); Wilking 2009 (64); Autier 2011 (65)
report and the subsequent English Cancer Strategy (2000), but
improvements in survival were not statistically significant (25).
Several international studies found that countries with
higher national income, and that spent a greater proportion
on healthcare, also had better survival rates (7;12;13;16;18).
This may be due to improved access to care. For example,
countries with higher national income may be able to afford
better equipped hospitals; the number of in-patient beds and
computerized tomography (CT) scanners per million popula-
tion were found to be positively associated with survival (16).
However, some of this improvement in survival may be an arte-
fact of improved detection methods (e.g., screening programs)
which increases the incidence of “over diagnosed” cancers (see
Table 1).
DISCUSSION
Our case study is not a definitive assessment of the validity of
our framework, but rather a first attempt to explore how a health
production approach can help identify the factors that should
be considered in an assessment of the relative effectiveness of
a new drug. These factors could potentially be used to opti-
mize effectiveness in routine practice. Engagement from broad
group of stakeholders (including providers) would be crucial to
the success of this process, and we set out below the types of
challenge they would need to resolve.
Choice of Outcome Measure
Cross-country differences in breast cancer outcomes are well
documented (6;7;13;14;64). However, the outcome measure
used to assess relative performance across countries can give
very different results in terms of ranking. When our three coun-
tries are assessed by 5-year survival rates, Sweden is ranked first
and the United Kingdom is ranked last (14); but an analysis of
mortality trends from 1989 to 2006 ranked Spain first and Swe-
den last (6). To understand this apparent discrepancy, we need
to recognize that survival is a “complex indicator of a country’s
performance” (7). Longer survival may reflect later death and/or
earlier diagnosis—and earlier diagnosis may reflect screening
intensity. But earlier diagnosis that does not lead to later death
is of questionable benefit to patients. Comparisons based on
survival may, therefore, be misleading, if differences in survival
do not reflect reductions in mortality. A recent international
comparison suggested screening did not play a direct part in
reductions in mortality (65). Both survival and mortality may
need to be considered alongside incidence if valid assessments
of prognosis are to be made (15;66).
Data Limitations
A limitation is thatwe have only identified factors reported in the
literature, and there may be other important drivers that have not
been assessed. For example, we found no study that isolated the
impact of hormone replacement therapy (HRT) on outcomes.
HRT is associated with an increase in the risk of breast cancer
(67;68), but only an estimated 3 of 100 breast cancers is related
to use of HRT (69). As use of HRT varies and breast cancers
induced by HRT may be less aggressive, variations in HRT
prescribing across countries are likely to influence international
differences in survival rates in a complicated way.
Most of the evidence related to the individual level, which
probably reflects data availability—cancer registries include an
array of patient characteristics, but comparable information on
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countries’ healthcare provider systems must be added from ex-
ternal sources. Where access to treatment was assessed, this
typically did not take account of dose or duration of treatment.
Conversely, we found more evidence on national factors, such
as screening programs. Subsequent studies need to further elu-
cidate the factors that may influence breast cancer outcomes,
ideally in consultation with clinical experts and possibly draw-
ing on additional (unpublished) data sources such as those docu-
menting differences in resource availability, or spend on breast
cancer. They would need to take account of evidence of the
impact of genetic variations on both prognosis and choice of
therapy.
Causality or Association?
A further shortcoming of our review is that it reports associ-
ations between health outcomes and various factors, but it is
less clear whether the relationships are causal. This is because
most of our studies are retrospective analyses of observational
data. The quality of this type of study is heavily dependent upon
the number of observations, the underlying data quality (which
is rarely reported in journal articles), the functional form of
the model and whether there are confounding factors that are
not, perhaps cannot be, taken into account. To explore causality
would require different study designs, such as randomized trials.
However, these are not feasible when investigating the impact of
national factors. Even if associations are robust, they shed little
light on drivers relating to the inputs and activities included in
the care given, which will impact on how a treatment is used and
what, if anything, it displaces. There may also be interactions
and correlations between the factors we identified, both within
and between different levels, for instance, national income is
likely to be correlated with individuals’ educational level and
individuals’ stage at diagnosis will be linked to system level
screening policy. This problem is perhaps more complex for
breast cancer than for some other diseases, such as acute con-
ditions, although most chronic diseases are managed through
a combination of screening, diagnosis, lifestyle alterations or
interventions, and drug treatment.
CONCLUSIONS AND POLICY IMPLICATIONS
Based on our review of studies comparing breast cancer out-
comes and of guidelines/HTA reports in three European coun-
tries, we believe that the way efficacy translates into relative
effectiveness across health systems is likely to be influenced by
a range of complex and interrelated factors. These comprise not
only the genetic and other biological and behavioral patient fac-
tors mentioned by Eichler et al. (2) (which we term “individual”
patient level factors in our model) but also the characteristics
of the providers and healthcare environment and system-level
factors. For example, the importance of stage at diagnosis begs
the question of why stage of disease differs across countries.
Arguably, this finding reflects the conclusion of Eichler et al.
(2) that “where there is an apparent large gap between efficacy
and effectiveness, one is not looking at a drug problem but at
a healthcare delivery problem, and the focus of remedial action
should be shifted to improving real life performance.”
Relative effectiveness is a current policy issue in Europe,
and this is why our case study is focused here. In principle, the
same issues arise in any context where drugs are approved cen-
trally but where there may be significant regional variations in
how the drugs are used in practice and, therefore, differences in
relative effectiveness. By recognizing that impediments to im-
proving health can arise at several levels, policy makers in any
jurisdiction can begin to explore ways to optimize relative effec-
tiveness. Studies that show differences in relative effectiveness
between countries, or that identify factors suggesting these ex-
ist, provide one way to identify how health system performance
can be improved.
Careful consideration of the determinants within our frame-
work may also aid discussions on the extent to which evidence
for HTA based decisionmaking can be shared across health sys-
tems, and identify the data required for robust comparisons. In
some cases, it will be reasonable to expect evidence on relative
effectiveness to be transferable; in other cases, it may be possi-
ble to anticipate and adjust for expected differences in relative
effectiveness between countries, and so use evidence from one
country in another. In other cases, however, an understanding
of relative effectiveness in a country may generate questions
that cannot be answered by existing evidence and that require a
bespoke study.
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